New Add-On therapy tested to slow Glaucoma's vision damage
NCT ID NCT06437639
Summary
This study tested whether adding the drug Mexidol to standard glaucoma treatment could help protect the optic nerve and slow vision loss. It involved 80 people with advanced primary open-angle glaucoma whose eye pressure was already controlled. Researchers measured changes in eye cell energy production and nerve fiber thickness to see if Mexidol provided extra protection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OPEN-ANGLE GLAUCOMA (POAG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tyumen Scientific Center of the Russian Academy of Sciences
Tyumen, Russian Federation, 625026, Russia
Conditions
Explore the condition pages connected to this study.